Keros Therapeutics, Inc.
NASDAQ:KROSBiotechnology
+$0.13 today
- Market cap
- $235.49M
- Beta
- 0.96
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.29
Volume 0.55M
Average 0.36M
KROS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Keros Therapeutics, Inc.NASDAQ: KROS
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns negative
Q1 FY2026 EBITDA was -$23.31M, compared with $158.84M a year earlier. Trailing-twelve-month EBITDA was -$88.74M.
Context
- EBITDA amounted to 38.3% of revenue in FY2025, down 5196.2 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of -$154.14M (-265.0%) for the fiscal year ending Dec 2026, a slowdown from the +150.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$23.31M+5.2% QoQ
- Last fiscal yearDec 2025
- $93.41M+150.3% YoY
- LTMMar 2026
- -$88.74M-376.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -114.7% | +17.5% | +132.2 pp |
| 1 year | +150.3% | -265.0% | -415.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 93.41M USD
- Year-over-year change
- +150.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 93.41M | +150.3% |
| FY2024 | 2024-12-31 | (185.82M) | -22.1% |
| FY2023 | 2023-12-31 | (152.18M) | -46.3% |
| FY2022 | 2022-12-31 | (104M) | -84.6% |
| FY2021 | 2021-12-31 | (56.35M) | — |
EBITDA vs competitors
How KROS compares with its peers on the latest reported figures
- KROS's LTM Mar 2026 EBITDA of -$88.74M is the 5th highest of the 10 companies compared; the peer median is -$106.84M.
- Its year-over-year change of -376.4% is the lowest of 10, against a peer median of -32.3%.
- EBITDA amounts to 267.4% of revenue for KROS, versus a peer median of 211.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $131.28M | +170.9% | — | 43.8% | |
NAGENiagen Bioscience Inc | LTM Mar 2026 | $21.4M | +33.4% | — | 16.4% |
| LTM Mar 2026 | -$42.27M | -2.3% | — | — | |
| LTM Mar 2026 | -$57.67M | -232.5% | — | 162.2% | |
| LTM Mar 2026 | -$88.74M | -376.4% | — | 267.4% | |
| LTM Mar 2026 | -$106.84M | -14.3% | — | 5818.9% | |
| LTM Mar 2026 | -$184.67M | -43.8% | — | — | |
| LTM Mar 2026 | -$191.95M | -32.3% | — | 387.1% | |
| LTM Mar 2026 | -$229.35M | -87.3% | — | 261.2% | |
| LTM Mar 2026 | -$245.81M | -69.1% | — | — | |
| Peer median (excluding KROS) | -$106.84M | -32.3% | — | 211.7% | |
Competitors are the stored peer set for KROS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 20.1M | 0 | 151K | 3.55M | 244.06M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.51M |
| Gross Profit | 20.1M | 0 | 151K | 3.55M | 242.55M |
| Gross Margin | 100.0% | — | 100.0% | 100.0% | 99.4% |
| Research & Development | 55.14M | 87.27M | 135.26M | 173.63M | 129.64M |
| Selling, General & Admin | 21.33M | 27.53M | 34.83M | 40.75M | 46.85M |
| Operating Expenses | 76.47M | 114.79M | 170.09M | 214.38M | 171.93M |
| Depreciation & Amortization | 378K | 674K | 815K | 1.23M | 1.51M |
| EBITDA | (56.35M) | (104M) | (152.18M) | (185.82M) | 93.41M |
| EBITDA Margin | -280.4% | — | -100779.5% | -5234.5% | 38.3% |
| Operating Income | (56.37M) | (114.79M) | (169.94M) | (210.83M) | 70.62M |
| Operating Margin | -280.5% | — | -112543.7% | -5939.0% | 28.9% |
| Interest Income | 0 | 1K | 0 | 0 | 0 |
| Interest Expense | 4K | 1K | 0 | 0 | 0 |
| Other Income / Expenses | (360K) | 10.11M | 16.95M | 23.78M | 21.27M |
| Income Before Tax | (56.73M) | (104.68M) | (152.99M) | (187.05M) | 91.9M |
| Pre-Tax Margin | -282.3% | — | -101319.2% | -5269.1% | 37.7% |
| Income Tax Expense | 2.01M | 0 | 0 | 300K | 4.88M |
| Net Income | (58.74M) | (104.68M) | (152.99M) | (187.35M) | 87.01M |
| Net Margin | -292.3% | — | -101319.2% | -5277.5% | 35.7% |
| EPS (Basic) | (2.52) | (4.15) | (5.20) | (5.00) | 2.34 |
| EPS (Diluted) | (2.52) | (4.15) | (5.20) | (5.00) | 2.30 |
| Weighted Avg Shares | 23.33M | 25.24M | 29.45M | 37.44M | 37.22M |
| Weighted Avg Shares (Diluted) | 23.33M | 25.24M | 29.45M | 37.44M | 37.86M |
Keros Therapeutics, Inc.
NASDAQ:KROS
Intrinsic Alpha fair value
Locked
Current Price
$12.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.